ARTICLE | Company News
Acorda, AstraZeneca, Mylan Inc. endocrine/metabolic, autoimmune news
March 28, 2016 7:00 AM UTC
The U.S. Court of Appeals for the Federal Circuit (CAFC) ruled that federal courts can preside over patent infringement cases involving ANDAs. The decision allows two cases involving Mylan to continue.
In 2014, Acorda filed suit against Mylan in the U.S. District Court for the District of Delaware alleging that Mylan’s ANDA for a generic version of multiple sclerosis drug Ampyra dalfampridine infringed Acorda’s patents. AstraZeneca filed suit in the same court, alleging Mylan’s generic versions of Onglyza saxagliptin and Kombiglyze XR infringed on patents covering the diabetes drugs. ...